Canadian Cancer Trials Group | Groupe canadien des essais sur le cancer

European Society for Medical Oncology (ESMO) Congress 2026
October 23-27, 2026
Madrid, Spain
Abstracts

CCTG GCC.1/SWOGS1823 - A Prospective Observational Cohort Study to Assess miRNA 371 for Outcome Prediction in Patients with Newly Diagnosed Germ Cell Tumours

Session Type: Rapid Oral Presentation
Session Title: Basic Science and Translational Research
Abstract #: LBA58
Abstract: ***Final results of S1823/GCC.1: A prospective observational cohort study to assess miR371a-3p (miR371) for outcome prediction in patients (pts) with newly diagnosed germ cell tumors (GCT)***
Authors: Nappi L, Colby S, Hamilton R, Harzstark A, Adra N, Daneshmand S, Ryan CW, Eggener S, Fung C, Johnson R, Lerner SP, Arnold K, Arun B, Rae JM, Blanke CD, Leblanc M, Parulekar WR, Einhorn LH, Kollmannsberger CK, Nichols CR
Link: https://www.annalsofoncology.org/article/S0923-7534(26)06835-3/fulltext

---

CCTG MA.40 - A Double-Blind Placebo Controlled Randomized Phase III Trial of Fulvestrant and Ipatasertib as Treatment for Advanced HER-2 Negative and Estrogen Receptor Positive (ER+) Breast Cancer Following Progression on First Line CDK 4/6 Inhibitor and Aromatase Inhibitor (FINER)

Session Type: Proffered Paper Presentation
Session Title: Breast Cancer, Early and Advanced Stage
Abstract #: LBA14
Abstract: ***A Double-Blind Placebo Controlled Randomized Phase III Trial of Fulvestrant and Ipatasertib as Treatment for HER-2 Negative and Estrogen Receptor Positive (ER+) Metastatic Breast Cancer (MBC): Overall Survival Results of the CCTG/BCT MA.40/FINER Study (NCT04650581).***
Authors: Redfern AD, Chia SK, Ayoub J, Chalchal HI, Rayson D, Rushton M, Desbiens C, Sabanathan D, Raphael J, Chan A, Singh J, Simmons C, Zdenkowski N, Wilson S, Rodin D, Cescon DW, Lattrich CC, Gallinaro L, Chen BE, Parulekar WR
Citation: https://www.annalsofoncology.org/article/S0923-7534(26)06785-2/fulltext

---

CCTG PR.21 - A Randomized Phase II Study of 177Lu-PSMA-617 vs Docetaxel in Patients with Metastatic Castration-Resistant Prostate Cancer and PSMA-Positive Disease

Session Type: Rapid Oral Presentation
Session Title: Genitourinary Tumours, Prostate, Penile and Testis
Abstract #: 2221RO
Abstract: ***Patient Reported Quality of Life (QoL) for Docetaxel (Doc) vs Lutetium177-617-PSMA (LuP) for Metastatic Castration-Resistant Prostate Cancer (mCRPC): Results from the Canadian Cancer Trials Group (CCTG) PR21 Trial***
Authors: Khalaf DJ, Chi KN, Saad F, Benard F, Soleimani M, Eigl BJ, Kolinsky MP, Azizi M, Fallah P, Rose AA, Ferrario C, Maurice-Dror C, Castilloux JF, Castonguay V, Sridhar S, Potvin KR, Smoragiewicz M, Brundage MD, Ding KU, Parulekar WP
Citation: https://www.annalsofoncology.org/article/S0923-7534(26)04007-X/fulltext

---

CCTG PR.22 - DASL-HiCaP: Darolutamide Augments Standard Therapy for Localized Very High-Risk Cancer of the Prostate. A Randomized Phase III Double-blind, Placebo-controlled Trial of Adding Darolutamide to Androgen Deprivation Therapy and Definitive or Salvage Radiation in Very High Risk, Clinically Localized Prostate Cancer

Session Type: Oral
Session Title: Presidential Symposium
Abstract #: LBA4
Abstract: ***Darolutamide with androgen deprivation therapy (ADT) and definitive or salvage locoregional radiation therapy (RT) for localised, very high-risk prostate cancer: Interim analysis of an international, placebo-controlled, randomised phase 3 trial (DASL-HiCaP; ANZUP1801)***
Authors: Niazi T, Thomas H, Zhang A, Williams S, Davis ID, McBride S, Chung H, Ebacher A, Khoo E, Martin J, Lim TS, Hughes S, Pryor D, Kelly PJ, Gholamrezaei L, Morgan S, Parulekar WR, Balicki G, Stockler MR, Sweeney CJ.
Citation: https://www.annalsofoncology.org/article/S0923-7534(26)06828-6/fulltext

---

CCTG CO.27 - A Phase III, Randomised, International Trial Comparing mFOLFIRINOX Triplet Chemotherapy to mFOLFOX for high Risk Stage III Colon Cancer in Adjuvant Setting

Session Type: **Proferred Paper**
Session Title: Gastrointestinal tumours, lower digestive
Abstract #: LBA29
Abstract: ***IROCAS: A randomized phase III trial of adjuvant treatment intensification with mFOLFIRINOX versus mFOLFOX6 in high-risk stage III (T4 and/or N2) colon cancer***
Authors: Bennouna J, André T, O'Callaghan C, Campion L, Mitry E, Gill S, Asmis TR, Mineur L, hiret S, Artru P, Perret C, Bouche O, Touchefeu Y, Dupuis O, Chibaudel B, Pezzella V, Marmorino F, Kavan P, Cremolini C, Taieb J
Citation: https://www.annalsofoncology.org/article/S0923-7534(26)06801-8/fulltext

---